e-learning
resources
Amsterdam 2015
Sunday, 27.09.2015
Safety of and interactions between current treatments for asthma and COPD
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Bronchodilator effect of high strength extrafine BDP/formoterol delivered via NEXThaler® in asthmatics
Mario Scuri (Parma, Italy), Brian Leaker, Adeep Puri, Mario Scuri, Sara Collarini, Annalisa Piccinno, Elena Carzana, Silvia Geraci, Dave Singh
Source:
International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD
Session:
Safety of and interactions between current treatments for asthma and COPD
Session type:
Thematic Poster Session
Number:
987
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Mario Scuri (Parma, Italy), Brian Leaker, Adeep Puri, Mario Scuri, Sara Collarini, Annalisa Piccinno, Elena Carzana, Silvia Geraci, Dave Singh. Bronchodilator effect of high strength extrafine BDP/formoterol delivered via NEXThaler® in asthmatics. Eur Respir J 2015; 46: Suppl. 59, 987
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: What’s NEW in the 2022 ERS/ATS PFT Interpretation Statement
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Related content which might interest you:
Study design supporting the effectiveness of inhaled extra-fine beclomethasone/formoterol at the level of small airways of asthmatics
Source: Annual Congress 2013 –Asthma drugs: new findings
Year: 2013
Efficacy of tiotropium Respimat® in adults with moderate asthma, by baseline LTRA use
Source: International Congress 2015 – Modulating the immune system in COPD and asthma
Year: 2015
Lung deposition analysis of two formulations of fluticasone/salmeterol HFA pMDI in stable asthma patients
Source: International Congress 2014 – Novel approaches and evidence for drug development in respiratory diseases
Year: 2014
High dose extrafine beclomethasone/formoterol via metered dose inhaler is effective and safe in asthmatics not controlled on medium-high dose of inhaled corticosteroids
Source: International Congress 2014 – Asthma and COPD management
Year: 2014
Tiotropium as add-on therapy to inhaled corticosteroids for patients with symptomatic asthma: Lung function and safety
Source: Annual Congress 2013 –LAMA, LABA, ICS and their combinations for the treatment of asthma and COPD
Year: 2013
Cardiovascular safety of extrafine beclomethasone/formoterol (BDP/FF) delivered via a novel dry powder inhaler (NEXThaler®) in COPD patients
Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD
Year: 2015
Prescribed doses and effect on asthma treatment outcomes of extrafine (ciclesonide) vs standard particle inhaled corticosteroids (ICS)
Source: International Congress 2015 – Novel targets and strategies for the treatment of cough, asthma, rhinosinusitis and COPD
Year: 2015
Tiotropium respimat: Comparison of bronchodilator efficacy of 5 and 2.5 µg doses
Source: International Congress 2014 – Asthma and COPD devices and treatments
Year: 2014
Once-daily tiotropium respimat add-on to ICS±LABA improves control across asthma severities
Source: International Congress 2014 – Bronchodilators for asthma and COPD
Year: 2014
Comparative efficacy and costs of the treatment of moderate to severe persistent asthma with a new dry-powder inhaled beclomethasone dipropionate and formoterol combination
Source: Annual Congress 2013 –Health economics of airway diseases
Year: 2013
Improved lung function and symptom control with formoterol on demand in asthma
Source: Eur Respir J 2006; 27: 504-510
Year: 2006
In-vitro emitted dose characteristics of combination budesonide / formoterol tubuhaler using patient inhalation profiles
Source: International Congress 2015 – Lung function: waiting to exhale...
Year: 2015
Systemic exposure and lung bioavailability across two different dose strengths of CHF5993 a novel Triple pMDI
Source: International Congress 2016 – Pulmonary drug delivery
Year: 2016
Efficacy and safety of indacaterol acetate on ICS background therapy in asthma
Source: International Congress 2014 – Asthma and COPD management
Year: 2014
Asthma control in asthmatics treated with extrafine or non-extrafine ICS/LABA combinations in real life setting
Source: Annual Congress 2013 –Diagnosis and management of respiratory diseases
Year: 2013
Comparable effectiveness of budesonide/formoterol combination and fluticasone for the treatment of cough variant asthma
Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs
Year: 2013
Efficacy of tiotropium and indacaterol alone or the combination on dynamic lung hyperinflation and exercise tolerance in COPD
Source: International Congress 2014 – Asthma and COPD management
Year: 2014
Effects of extra fine formoterol or coarse particle salmeterol on impulse oscillometry (IOS) in corticosteroid treated persistent asthmatics
Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD
Year: 2015
Assessment of the bioequivalence of two DPIs containing fluticasone and salmeterol, in patients with controlled or partly controlled asthma
Source: International Congress 2016 – Clinical characteristics of asthma
Year: 2016
The add-on effect of tiotropium bromide to ICS/LABA combination inhaler for the patients with severe uncontrolled asthma
Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD
Year: 2015
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept